MassBio report details challenges spanning China, NIHnews2026-08-26T17:28:41+00:00August 26th, 2026|Endpoints News|
An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapiesnews2026-08-26T14:24:29+00:00August 26th, 2026|Endpoints News|
Exclusive: Faro raises $37M Series B to speed up clinical trials with AInews2026-08-26T11:00:59+00:00August 26th, 2026|Endpoints News|
ARCH and Population Health join China blitz with Haisco dealnews2026-08-25T14:15:05+00:00August 25th, 2026|Endpoints News|
Option-to-acquire deals remain rare in biotech’s buzzy M&A seasonnews2026-08-24T10:30:05+00:00August 24th, 2026|Endpoints News|
Abcuro gets $66M for Phase 3 in muscle-weakening conditionnews2026-08-14T15:28:46+00:00August 14th, 2026|Endpoints News|
Boulevard Bio dreams big in immunology with $65M, sights on Vera’s IgAN drugnews2026-08-12T10:30:11+00:00August 12th, 2026|Endpoints News|
Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series Anews2026-08-11T12:00:44+00:00August 11th, 2026|Endpoints News|
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatmentnews2026-08-11T11:00:15+00:00August 11th, 2026|Endpoints News|
BioNTech vets get $25M seed funding for virtual cancer surveillance startupnews2026-08-10T11:00:22+00:00August 10th, 2026|Endpoints News|
